MK-1084
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for MK-1084, covering 2026-04-09 to 2026-04-24. Get the full timeline:
Most recent: Clinical Trial Update: KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) [Phase 2]